​

Funding Round

Series A - Myeloid Therapeutics

Series A - Myeloid Therapeutics

Investment Firm

Overview

Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.

Announced Date

May 18, 2023

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Hatteras Venture Partners

Hatteras Venture Partners

Hatteras Venture Partners is a convertible_note and early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorAlexandria Venture Investments
Participant InvestorNewpath Management
Participant InvestorHatteras Venture Partners
Participant Investor8VC
Participant InvestorARCH Venture Partners

Round Details and Background

Myeloid Therapeutics raised $73000000 on 2023-05-18 in Series A

Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 06, 2021
Series A - Myeloid Therapeutics
4-50.0M
Feb 20, 2023
Grant - Myeloid Therapeutics
1-66.3M
May 18, 2023
Series A - Myeloid Therapeutics
6-73.0M

Recent Activity

There is no recent news or activity for this profile.